Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer

Study ID
NCT02117466

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Terminated

Trial Acronym

IMPACT-CRC

Trial Summary

In this study the investigators will evaluate the uptake of 89Zirconium labeled cetuximab in extra-hepatic colorectal metastases. The investigators hypothesize that uptake of 89Zr-cetuximab is required for response to cetuximab. If no uptake is present the investigators will escalate the dose cetuximab and repeat the 89Zr-cetuximab PET. The investigators will evaluate the clinical benefit rate of cetuximab in the patients with and without uptake. The ultimate goal is to create a selection tool that can predict response of cetuximab.

More informations

Trial Starting Date

Apr 30,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit